Augsburg University

Idun
Theses and Graduate Projects
7-26-2020

Comparison of Non-NSAID Pain Management in the Treatment of
Patients with Symptomatic Knee Osteoarthritis
Nicholas Schmitz

Follow this and additional works at: https://idun.augsburg.edu/etd
Part of the Orthopedics Commons

Comparison of Non-NSAID Pain Management in the Treatment of
Patients with Symptomatic Knee Osteoarthritis
By,
Nicholas Schmitz
Alicia Quella PhD PA-C

Paper Submitted in Partial Fulfillment
Of the Requirements for the Degree
Of Master of Science
Physician Assistant Studies
Augsburg University
07/26/2020

Table of Contents
ABSTRACT................................................................................................................................................................... 1
INTRODUCTION ........................................................................................................................................................ 4
BACKGROUND ........................................................................................................................................................... 5
LAND-BASED AND AQUATIC ACTIVITY .................................................................................................................... 5
ORAL AND INTRA-ARTICULAR CORTICOSTEROIDS ................................................................................................. 8
DULOXETINE ........................................................................................................................................................... 10
INTRA-ARTICULAR OZONE (O3) INJECTIONS ......................................................................................................... 13
GLUCOSAMINE SULFATE ........................................................................................................................................ 15
INTRA-ARTICULAR PLATELET RICH PLASMA (PRP) INJECTIONS ....................................................................... 18
INTRA-ARTICULAR HYALURONIC ACID INJECTIONS ............................................................................................ 22
INTRA-ARTICULAR DEXTROSE PROLOTHERAPY ................................................................................................... 24
INTRA-ARTICULAR MESENCHYMAL STEM CELL INJECTIONS .............................................................................. 26
CONCLUSION ........................................................................................................................................................... 29
REFERENCES ........................................................................................................................................................... 35
APPENDIX A .............................................................................................................................................................. 39
TABLES ..................................................................................................................................................................... 39
APPENDIX B .............................................................................................................................................................. 46
FIGURES .................................................................................................................................................................... 46

Non-NSAID Pain Management in Symptomatic KOA | Page 1

Abstract
Objective
To compare the efficacy of other modalities and interventions versus standard first-line
therapy of nonsteroidal anti-inflammatory drugs for pain management in patients with
symptomatic knee osteoarthritis
Methods
Perform literature reviews outlining patients suffering from Grade II or higher KOA
using the Kellgren-Lawrence classification system and currently experiencing symptoms
of pain, stiffness, and impaired physical functioning. Use data and results from various
studies to compare improvement of symptoms from these modalities versus improvement
of NSAIDs alone.
Results
Weight loss and physical activity should remain the mainstay of early osteoarthritis
treatment to help slow disease progression and symptoms of KOA. Duloxetine has been
shown to be non-inferior to treatment with NSAIDs and improved patient physical
functioning and quality of life. Oral and intra-articular corticosteroids remain superior or
equal in pain reduction but have a shorter duration of action and greater adverse reactions
when taken long term. Ozone therapy is best used in post-operative pain management or
severe flares of osteoarthritis to quickly reduce pain and inflammation, long term therapy
is not recommended over NSAIDs. Glucosamine does not decrease pain related to KOA
but when used concomitantly with NSAIDs can increase physical function, quality of life,
and also slow disease progression. LP-PRP injections have greater efficacy and resulted
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in lower WOMAC total scores at three, six, and twelve-month intervals when compared
to ozone, hyaluronic acid, and corticosteroid injections. LP-PRP injections also have
greater or equal efficacy of hyaluronic acid plus oral NSAIDs at one year. PRP therapy
also has some evidence to suggest disease modifying potential. Hyaluronic acid injections
resulted in less joint line tenderness and better physical functioning when compared to
NSAID therapy alone, however, reduction in pain was not statistically significant.
Prolotherapy was shown to be equally effective as PRP injections at pain reduction but
requires serial injections. Benefit of prolotherapy is its safety profile and cost
effectiveness. Finally, stem cell therapy resulted in lower WOMAC total scores when
compared to hyaluronic acid injections. T2 MRI mapping indicates the ability of
mesenchymal stem cells to regenerate cartilage and slow disease progression.

Conclusion
NSAIDs remain the most efficient means of pain reduction but do not result in
statistically significant increases in physical function or quality of life. Hyaluronic acid
can increase the patients physical functioning if used alone or in combination with
NSAID therapy. Oral glucosamine sulfate, if taken daily, can reduce the progression of
osteoarthritis but provides no pain relief if taken alone or without NSAIDs. Oral or intraarticular corticosteroids should be reserved for severe flares of pain in which the patient
is unable to perform daily activities secondary to disability. Adverse reactions and
possible further joint degeneration remain the biggest concern. Duloxetine should be
considered in patients suffering chronic and refractory pain related to KOA and can be
used in addition to NSAIDs to provide long term relief. Clinically the use of ozone
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therapy is not relevant and pain reduction can be achieved in other modalities, use of
ozone is best reserved for post-operative management to reduce inflammation. PRP
injections are clinically relevant and provide statistically significant reductions in pain
and disease progression. Use should be considered in patients who have failed other
conservative KOA treatments. Finally, the use of mesenchymal stem cells does alter
disease progression and reduce pain, but clinically its use is not relevant because the
harvesting and cost are greater than other effective therapies currently. More evidence is
needed to support its clinical use. In conclusion, alternative modalities should be
considered if therapy with NSAIDs is not providing adequate reductions in pain or the
goals of the patients are not being met. The aforementioned modalities are safe and
effective adjuvant therapies to manage patients with symptomatic KOA.
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Introduction

Osteoarthritis (OA) is the most common joint disorder in the United States, estimated to
affect nearly 12% of adults ages 25-74.[1] Not all adults affected with osteoarthritis are
symptomatic or seek treatment, leading to a slightly lower estimated prevalence. Regardless of
actual prevalence, knee osteoarthritis (KOA) is the most frequent form OA and in 2004
accounted for 430,000 hospital discharges and roughly $14 billion in medical expenses.[2]
According to Murphy L, Schwartz TA, Helmick CG, et al adults the lifetime risk of developing
symptomatic KOA for both men and women is 40%-46% with little variation regarding race.
However, this percentage increases to 56% if an adult suffers a significant knee injury during
their lifetime and increases to an even greater 61% if the person is obese (Table 1, Appendix
A).[2] Given the aging population and the increasingly sedentary lifestyle leading to diabetes,
overweight, and obesity the projected incidence of KOA is estimated to continually rise and,
therefore, cost the average US citizen more in medical expenses.
Understanding the etiology of KOA will further delineate the increasing likelihood of one
suffering from joint disease. Osteoarthritis, specifically KOA, has a multifactorial etiology
including age, sex, race, BMI, history of traumatic injury, physical activity, sedentary lifestyle,
congenital, or acquired joint/ligamentous laxity. The etiologies and epidemiology of KOA
demonstrate the importance of advancing treatment and modalities to help treat patients with
symptomatic joint disease. First-line therapy for OA combines oral or topical non-steroidal antiinflammatory drugs (NSAIDs) and non-pharmacologic management with moderate aerobic
weight-bearing activity, physical therapy, weight loss, etc. Treatment with NSAIDs is feasible in
a patient with a younger age or no comorbidities, however, KOA is a chronic progressive disease
and tends to span decades and often requires combination pharmacological therapy. Therefore,
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providers should be aware of and utilize other treatments and modalities to provide better pain
relief and improved functioning to their patients. The purpose of the study is to compare the
efficacy of other modalities and interventions versus standard first-line therapy of nonsteroidal
anti-inflammatory drugs for pain management in patients with symptomatic knee osteoarthritis.
The objectives demonstrating improved pain, functioning, and stiffness will be achieved using a
variety of large studies on the topics of land-based or aquatic activity, corticosteroids,
glucosamine sulfate, duloxetine, platelet-rich plasma (PRP) injections, hyaluronic acid
injections, ozone therapy, dextrose prolotherapy, and mesenchymal stem cell injections.
Background
Land-Based and Aquatic Activity
Osteoarthritis is occasionally called "wear-and-tear" arthritis because the development of
OA is typically seen in older patients who have placed continued stress on their joints throughout
a lifetime. However, describing KOA as "wear-and-tear" can be significantly misleading for
patients and possibly deter them from participating in physical activity. According to a 2012
study from the American College of Rheumatology physical activity is strongly recommended
for symptomatic KOA, however, they expressed no preference for either land-based or aquatic
exercise.[4] A common concern among patients is the possible worsening or progression of their
joint disease if they continue performing daily activities or an exercise routine. The patient must
understand the importance of physical activity for the positive systemic effects but also local
joint health and protection. Exercise is known to have profitable trophic effects on periarticular
bone and muscle in particular, and also tendon.[6] Similar effects are seen in the articular
cartilage and many studies suggest that articular cartilage is mechano-adaptive; that is, the
biosynthetic activity of chondrocytes is responsive to mechanical stimuli and can alter the
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morphology and composition of cartilage.[6] Understanding the physiological of the effect on
cartilage and bones, can it be used at monotherapy to treat patients with symptomatic KOA and
provide equal relief compared to NSAIDs?
First, the notion of mild to moderate physical activity increases the likelihood of KOA
must be eliminated. According to several retrospective and prospective cohort studies spanning
roughly 18 years, there is no evidence routine land-based physical activity increases the
likelihood or incidence of KOA in study participants. However, activities that placed the
participants at increased risk for injury such as, heavy resistant weight training or competitive
sports increased the incidence of KOA secondary to traumatic injuries alone.[8] Several other
mechanical factors during physical activity can place an individual at risk for development or
progression of KOA, but the act of exercise or activity is not the cause for this development
(Figure 5, Appendix B).
One randomized clinical trial aimed to demonstrate the efficacy of physical activity when
compared to routine care and symptomatic management. Kovar et al. enrolled 102 patients in
either an eight-week supervised fitness and patient education program (n=51) or routine medical
care (n=51). The eight-week program consisted of twenty-four 90-minute walking and education
sessions which were designed and lead by registered physical therapists. These sessions occurred
three times per week and included a light stretch, strengthening exercises, guest speakers on the
medical aspects of osteoarthritis and exercise, group discussions, supportive encouragement, and
about 30 minutes of walking. The researchers performed the walking sessions in the same
hospital corridor with similar walking shoes, socks, and loose fit athletic clothing. The control
group was instructed to perform similar physical activities unsupervised and was contacted
weekly via telephone to discuss their activities of daily living. Functional improvement outcomes
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were measured using a six-minute walking distance test and the Arthritis Impact Measurement
Scale (AIMS). The AIMS arthritis pain subscale was used to assess pain and the medication
subscale was used to assess medication use related to arthritis. The AIMS medication subscale is
inversely related and the higher the number the less frequent the medication usage.
In the experiment group, following the interventions, walking distance improved an
average of 70 meters, which reflects about an 18.4% increase from baseline. On the other hand,
the control group decreased an average of 17 meters from baseline (P <0.001). Furthermore, for
the control group, the AIMS physical activity subscale reflected virtually no change. The study
group demonstrated an improvement in 2.41 units from baseline, which is an improvement of
about 39% and therefore statistically significant (P <0.001). In summarization, the AIMS sub
scores, on average, improved about 25% in the study group. Interestingly, the AIMS medication
subscale increased by 0.84 units in the study group, which reflects the need for less rescue
medication use.[42]
Land-based aerobic activity has been proven to decrease pain and disability, can aquatic
exercise perform similarly? A large Cochrane review of thirteen studies comparing aquatic
exercise and control demonstrates the effectiveness of aquatic exercise. The authors were
studying the effects of interventions on pain, disability, and quality of life. The analysis of twelve
out of the thirteen trials showed a statistically significant pain reduction (SMD −0.31, 95%
C:−0.47 to −0.15). Disability, similarly, showed a statistically significant reduction following
about 12 weeks of aquatic exercise (SMD −0.32, 95% CI −0.47 to −0.17). Ten out of the thirteen
trials in the analysis also show a statistically significant improvement in quality of life (SMD
−0.25, 95% CI −0.49 to −0.01).[43]
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Oral and Intra-articular Corticosteroids
Pharmacologic intervention with corticosteroids in patients suffering from symptomatic
KOA has been utilized clinically for several years. The mechanism of action for corticosteroid
medications is similar to NSAIDs, however, corticosteroids are a more potent inhibitor of
inflammation. Corticosteroids have a complex mechanism of action by acting on the nuclear
steroid receptors to interrupt the inflammatory cascade on several levels. They reduce vascular
permeability and inhibit accumulation of inflammatory cells, phagocytosis, production of
neutrophil superoxide, metalloprotease, and metalloprotease activator, and prevent the synthesis
and secretion of several inflammatory mediators such as prostaglandin and leukotrienes.[7] The
prevention of prostaglandins and leukotrienes proves to provide relief for symptomatic KOA
because these inflammatory mediators are directly involved in the patients’ pain response.
Several routes and dosages are used when administering corticosteroids and the most common in
the treatment of KOA are oral or intra-articular, both will be discussed at length.
The benefits of oral corticosteroid therapy for symptomatic KOA are ease of access, cost,
and route form. Corticosteroids tend to be easily accessible for both patients and providers and
cost tends to be around $1 per pill.[10] The risks of oral corticosteroid therapy are numerous and
must be taken into account. The risks are as follows and certainly not limited to fractures (most
commonly vertebral), moon face or rubicundity, depression, gastrointestinal symptoms, gastric
ulcers, tinnitus, psychosis, acute infections, diabetes, and hypertension. A prospective cohort
study demonstrated the long-term adverse effects of continuous low-dose prednisolone on 122
patients for 10 years and found 31 patients suffered fractures, 5 experiences osteonecrosis, and
36 developed cataracts.[9] Conversely, low-dose prednisolone is not only highly effective for
short-term therapy, but also significantly more effective than non-steroidal anti-inflammatory

Non-NSAID Pain Management in Symptomatic KOA | Page 9
drugs. (Table 2, Appendix A) A systematic review of the effect of low dose prednisolone after
six months also found a significantly better effect of the drug than of placebo. Prednisolone also
had a greater effect than non-steroidal anti-inflammatory drugs on joint tenderness (SMD = 0.63, 95% CI -1.16 to -0.11) and pain (SMD = -1.25, 95% CI -2.24 to -0.26). [9] Similar to
NSAIDs, corticosteroids are used as rescue medication during flares or increases of KOA related
pain and should not be used as long-term or prophylactic medication given the negative adverse
effects. After interpreting the data, patients who can tolerate short “bursts” of oral corticosteroids
during periods of increased pain due to KOA can see significant reductions in pain and
improvement in joint line tenderness.
Intra-articular corticosteroid therapy has the same mechanism of action as oral therapy
resulting in a reduction of pain and inflammation. The benefit of intra-articular infiltration
involves less systemic absorption and therefore, less negative adverse reactions commonly seen
with corticosteroid therapy. Typically larger joints receive a greater amount of injected
corticosteroid and risk greater systemic absorption. The most common adverse reaction is seen in
patients with diabetes, all with previously well controlled blood sugar levels, who received intraarticular corticosteroids concurrently had a transient increase in blood sugar levels, some as high
as 300mg/dL.[11] A more potent inhibitor of cytokines and leukotrienes with less systemic
absorption and possible side effects, why is this not first-line treatment for symptomatic KOA?
A randomized control study containing 70 participants with ages averaging 53 years old
was performed to compare the efficacy of oral NSAIDs and intra-articular corticosteroid
injections in the reduction of rheumatoid arthritis related knee pain. Participants were divided
into two groups, one group receiving diclofenac 150mg and aceclofenac 200mg two times per
day for 21 days. The other participants were designated into a steroid group and received three
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administrations of either cortivazol 75mg or betamethasone 2mg at one-week intervals. All
participants were monitored for another six weeks and the NSAID group had a greater
improvement in pain, functioning, and stiffness (Table 3, Appendix A) from initiation until day
42 of the study.[12] Additionally, three limitations must be discussed in this study possibly leading
to bias or ambiguity. The authors failed to report or document side effects from either treatment,
participants in the NSAIDs group were roughly 13 years older on average, and the intra-articular
steroid group had higher reported baseline pain and greater reported functional impairment than
the NSAIDs participants.
These results suggest that a combination of both NSAIDs and intra-articular steroid
treatments may be performed for optimal pain relief and functional improvement. For example, a
patient regimen could be similar to a steroid infiltration on the first day followed by the treatment
of NSAID two times daily until resolution up to 21 days. If the patient cannot tolerate the
procedure of an intra-articular steroid injection or NSAIDs are contraindicated, oral prednisone
may be another alternative but adverse reactions must be closely monitored. Furthermore, dual
therapy with NSAIDs and steroids is contraindicated secondary to increased risk of
gastrointestinal symptoms and ulceration.
Duloxetine
The mechanisms underlying the pain of osteoarthritis are chronic, progressive, and
complex. There is evidence that central sensitization contributes to the chronic pain associated
with KOA, and dysfunction of the descending pain inhibitory system contributes can contribute
to the central sensitization. Duloxetine, a selective norepinephrine reuptake inhibitor (SNRI),
typically used in depression and neuropathic pain, has shown some analgesic properties in pain
related to KOA.[16, 17] The exact mechanism of action by which duloxetine inhibits pain is
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unknown. Although, it is presumed to activate the descending pain inhibitory system in the
dorsal spinal horn due to the effects of increasing serotonin and norepinephrine levels in the
synaptic cleft of the spinal and supraspinal pathways.[17] NSAIDs have been proven effective in
treating synovitis due to cartilage degeneration, however, central sensitization may prove to be
an equal contributor to pain generation in KOA. Therefore duloxetine, in theory, may prove
effective in treating central sensitization contributing to pain seen in chronic KOA.
A randomized, placebo-controlled study in Japan enrolled 353 participants with KOA to
compare the efficacy of duloxetine versus placebo. The study group was further divided into
subgroups pertaining to previous NSAID use three months prior to treatment initiation. Subgroup
1 had no prior NSAID use, subgroup 2 used NSAIDs less than 14 days per month, subgroup 3
used transdermal NSAIDs more than 14 days per month, and subgroup 4 used NSAIDs more
than 14 days per month. Participants' pain was measured at baseline using the BPI 24-hour
average pain scale. A secondary efficacy measurement was utilized by measuring the WOMAC
pain, stiffness, and physical function subscales. The control group received a placebo while the
study group received duloxetine 20mg capsules once daily for one week, two 20mg capsules for
one week, and three 20mg capsules for 12 weeks. Both groups also received analgesic rescue
medication which was permitted for up to three consecutive days and a cumulative total of 20
days. NSAIDs were permitted as rescue medications but the use of tramadol hydrochloride was
forbidden.
During the 14 weeks treatment period, the study group receiving duloxetine required less
rescue medication than the control group receiving placebo, regardless of previous NSAID usage
Similarly, the BPI 24-hour average pain severity scale was lower at all times during the 14 weeks
treatment period for the group receiving duloxetine in all subgroups (See figure 2, Appendix A).

Schmitz | Page 12
Finally, WOMAC pain, stiffness, physical function, and total scores had greater reductions in all
subgroups receiving duloxetine compared to placebo.[17] Given the results from the study,
duloxetine may prove effective as an alternative treatment for pain related to KOA in patients.
This is particularly beneficial in patients with cardiovascular or gastrointestinal comorbidities
and a benefit-to-risk discussion is warranted. Enomoto et al. demonstrated duloxetine is more
effective than a placebo at reducing pain, yet, is it more effective than NSAID therapy?
Myers et al. performed a meta-analysis of 32 randomized control studies demonstrating
the efficacy of NSAIDs, duloxetine, and opioids in the management of KOA related pain.
Studies were included only if the duration was greater than or equal to 12 weeks and the
participant's pain was graded using the WOMAC total score. The outcome measure for the metaanalysis was a change in reported 12 weeks of WOMAC total scores compared to baseline
WOMAC total scores. Estimated treatment effects of ibuprofen, naproxen, celecoxib, etoricoxib,
tramadol, oxycodone, and hydromorphone were compared to placebo and compared to
duloxetine were calculated with their 95% confidence intervals using the Bucher method of
indirect comparison.[18] Using the frequentist analysis the results of the indirect comparison
versus duloxetine showed duloxetine was superior to tramadol, celecoxib, and hydromorphone in
reducing WOMAC scores from baseline (See Table 4, Appendix A). On the other hand, the
authors also performed a Bayesian analysis using an indirect comparison versus duloxetine and
adjusted for baseline WOMAC total scores which resulted in a probability duloxetine superiority
over several other treatments (See Table 4, Appendix A). Duloxetine exhibited superiority over
tramadol and hydromorphone with a probability of 1. Similarly, the probability duloxetine is
superior to ibuprofen and celecoxib was 0.82 and 0.76 respectively. One notable limitation in the
study was the number of randomized clinical trials used in the comparison of duloxetine over
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oxycodone. The authors only used one study for adjusted baseline WOMAC total scores, in
comparison to celecoxib, which had a total of 14 trials. Hydromorphone was shown inferior to
duloxetine with 100% probability and potentially if more trials were used in the study,
oxycodone would also be shown inferior.
The studies of Enomoto et al. and Myers et al. validate duloxetine superiority when
compared to placebo. Myer et al. establish duloxetine is non-inferior to all other first-line
medications in the management of KOA, except etoricoxib, and is more beneficial in reducing
WOMAC total scores than hydromorphone and tramadol. Clinically this can be utilized by
providers seeking safe and effective alternative treatments for chronic pain related to KOA.
Intra-articular Ozone (O3) Injections
Oxygen-ozone solution can improve tissue oxygenation and inhibit inflammatory
mediators mediated by the down-regulation of TNFα and TNFR2. Ozone therapy can also induce
moderate-intensity oxidative stress and inhibit inflammatory responses. Ozone also has a
relatively moderate analgesic effect through phosphodiesterase A2 blockage.[19] Therapy with
ozone first began in 1987 as a possible treatment for abscesses, acne, HIV, cerebral sclerosis,
wound healing, and numerous other pathologies. Throughout the next several decades, ozone
therapy has continually evolved and has evidence of anti-viral and anti-bacterial properties,
reduce the activity of tumor cell suspensions from the breast and colon, and reduce abscess
formation with irrigation.[23] More so, in the past decade, there has been increasing investment
into ozone therapy for the symptomatic relief of pain related to KOA. Ozone injections are an
effective and low-cost procedure to help symptoms. Is ozone therapy effective enough to limit or
discontinue the use of NSAIDs?
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A retrospective observational study evaluated 80 patients suffering from KellgrenLawrence Grade II or III symptomatic KOA who received intra-articular ozone therapy
following arthroscopic debridement. The control group following arthroscopic surgery did not
receive ozone injections and the study group received 20ml of 20mg/mL of ozone post-surgery.
The participants were followed for 12 months and efficacy outcomes were measured using
WOMAC total scores, Lequesne, and the VAS score at 6 weeks, 3 months, 6 months, and 12
months. It was observed that the VAS scores significantly decreased from 7.52 prior to treatment
to 5.17 at the 12- months follow-up in the ozone group, whereas in the control group, the VAS
scores decreased from 7.66 to 6.56 (Figure 3.2, Appendix B).[21] The Lequesne Index improved
from 15.07 to 8.74 in the ozone group and from 14.26 to 10.08 in the control group at the
12‑month follow‑up (Figure 3.1. Appendix B).[21] Finally, the total WOMAC score improved to
41.19 from 70.43 in the ozone group, and 58.84 from 73.68 in the control group at the 12‑month
follow‑up (Table 5, Appendix A).[21] Wang et al. demonstrate the efficacy of O3 injections in the
management of post-arthroscopic pain control compared to placebo. Clinically this is relevant
because often times NSAIDs are withheld following orthopedic surgeries or fractures on the
basis they may decrease boney healing.
Ozone injections have proven an effective alternative medication in the management of
patients suffering from KOA related or post-operative pain, but is it superior to NSAIDs? An
interventional study performed by Feng et al. aimed to evaluate the effect of intra-articular ozone
in KOA related pain compared to taking oral celecoxib and glucosamine. The study enrolled 76
patients currently suffering Kellgren-Lawrence Grade II or III symptomatic KOA and randomly
assigned them into two groups. The control group took oral celecoxib 200mg one time in the
morning and glucosamine hydrochloride 240mg every morning, afternoon, and night for a total
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of six weeks. The study group received 20ml of 20mg/mL ozone intra-articular two times per
week for six weeks along with the same oral regimen of the control group. The randomly
assigned groups were deemed to have no statistically significant difference in demographics,
Lysholm scores, or baseline VAS scores prior to initiation, effectively ruling out bias. As
previously mentioned, efficacy outcomes measured using the VAS score for pain and the
Lysholm knee score for the functional ability of the knee.[22]
At the end of the six weeks, the pain score and the function of the knee between the two
groups had no significant difference. However, the function improved quicker in the ozone plus
celecoxib and glucosamine hydrochloride group compared to the control. The exact mechanism
by which the pain resolved quicker is unknown but is believed to be due by the reduction of
inflammation by both the oral anti-inflammation medicines and the ozone injections which have
different mechanisms of action.[22] A determination for the efficacy of ozone injections over
NSAIDs could not be concluded given the previous studies, conversely, intra-articular ozone
injections are proven to decrease pain and increase function faster than NSAID therapy alone.
Furthermore, intra-articular ozone therapy is more effective in pain reduction and physical
function when compared to placebo.
Glucosamine Sulfate
Historically the treatment of osteoarthritis has centered around symptomatic relief of pain
and improvement of stiffness and functional ability. Symptom modifying, typically NSAIDs, are
the present prescription of choice for symptomatic OA. However, the search for a possible
disease-modifying or biological agent has been the goal for several years, glucosamine sulfate
appears to be the most readily available and promising. Glucosamine is the most fundamental
building block required for the biosynthesis of the classes of compounds including glycolipids,
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glycoproteins, hyaluronate, and proteoglycans. These compounds play an important role in the
synthesis of cell membranes or linings, collagen, osteoid, and boney matrix. Finally,
glucosamine is also required for the formation of lubricants and protective agents such as mucin
and mucous secretion.[13, 14] Glucosamine sulfate is most commonly extracted from the shells of
shellfish such as shrimps, crabs, and lobsters, and must be avoided in patients with allergies to
these animals.
As previously mentioned, this biological agent is readily available and shows the most
promise for a possible disease-modifying OA agent, nevertheless, does it produce enough
symptomatic relief for patients to warrant use over NSAIDs or limit the need for NSAIDs? A
2012 clinical study to determine the efficacy of glucosamine sulfate alone versus glucosamine
sulfate in addition to NSAIDs was performed to help answer this question. The study enrolled 82
patients suffering from mild to moderate KOA, identified radiographically using the KellgrenLawrence scale, and were divided into group A and group B. Group A consisted of 43 patients
who were treated with 500mg glucosamine sulfate three times per day. Group B consisted of 39
patients and was treated with 500mg glucosamine sulfate three times per day plus either
Ibuprofen or Piroxicam once daily. Both groups would be reassessed every 30 days for 3 months
using the WOMAC pain, stiffness, and function scores in addition to the VAS score. The mean
WOMAC total score of group A on week zero was 47.65 ± 3.69 and after four weeks increased
to 48.09 ± 2.23. However, at 12 weeks and completion of the trial, the mean WOMAC total
score for group A was 30.58 ± 1.41 with the mean difference being 17.06 ± 4.54. Using the Pvalue (P < 0.01), the mean score decrease was statistically highly significant. On the other hand,
the mean WOMAC total score of group B was 50.76 ± 3.88 on week zero and decreased to
39.64 ± 4.31 after four weeks. After 12 weeks, the mean WOMAC total score was 14.79 ± 3.16
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with the mean difference of 35.97 ± 4.24. The result of group B revealed that the mean score
decrease was statistically highly significant (P < 0. 01). Continuing to use the P-value and
comparing the results of group A and B revealed a significant difference between the two groups
(P < 0.01). Similar to the WOMAC, the secondary efficacy variable using the VAS score results
in a higher mean difference in group B following the conclusion of the study at 12 weeks.[15]
Interpreting the data from Selvan et al. is apparent in combination therapy with NSAIDs,
and glucosamine sulfate resulted in highly significant reductions in pain and stiffness and
increased physical functioning. Unfortunately, the study does not completely answer whether
glucosamine sulfate alone is more effective than NSAIDs alone. Clinically the study remains
relevant by demonstrating the efficacy of combination therapy with NSAIDs and glucosamine
sulfate in maintaining and improving patient quality of life.
Glucosamine sulfate alone or in combination with NSAIDs can significantly reduce
symptoms of KOA, but can it slow the progression of OA and possibly reduce the need for future
NSAID usage? Pavelká et al. performed a three-year randomized, placebo-controlled, doubleblind study aimed at determining the efficacy of glucosamine sulfate in limiting the progression
of joint structure and symptom changes in KOA. The study enrolled 200 patients and was
randomized to receive either placebo or 1500mg glucosamine sulfate once a day. Radiographs
were taken at enrollment and after 1, 2, and 3 years of treatment by the same technician using the
same x-ray machine and approach. The study utilized anteroposterior weight-bearing plain films
with the participant's heels and toe together with the knees in full extension. The primary
outcome measure was represented by joint space change in the narrowest medial compartment of
the tibiofemoral joint. Placebo-controlled participants demonstrated progressive joint space
narrowing of -0.19mm (95% CI, -0.29 to -0.09mm) after 3 years. The glucosamine sulfate study
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group experienced no average change (0.04mm, 95% CI, -0.06 to 0.14mm). See Figure 1 in
Appendix B for more year-to-year detail. The difference between the two groups (P = .001) is
statistically highly significant. Results of the study demonstrated long term therapy with 1500mg
glucosamine sulfate slowed KOA disease progression utilizing joint space narrowing.[16]
The results of both Pavelká et al. and Selvan et al. demonstrate glucosamine sulfate can
be used to slow disease progression for patients with diagnosable mild to moderate KOA and can
be used in combination with NSAIDs to increase symptomatic relief of pain and stiffness.
However, KOA is a chronic and progressive condition and the limitation of the studies is the lack
of substantial time of monitoring. Furthermore, the studies of Pavelká et al. cannot fully
determine the efficacy of glucosamine sulfate use prophylactically prior to the diagnosis or
symptoms of KOA.
Intra-articular Platelet Rich Plasma (PRP) Injections
Intra-articular platelet-rich plasma injections have been shown to decrease chondrocyte
apoptosis, increase proteoglycans in the articular cartilage, and prevent against OA progression.
The mechanism of action within the joint is unknown but is thought to provide relief by
delivering a broad spectrum of growth factors such as insulin-like growth factor, transforming
growth factor b-I, platelet-derived growth factor, etc. It is also thought to deliver other active
molecules such as cytokines, chemokines, arachidonic acid metabolites, extracellular matrix
proteins, nucleotides, ascorbic acid to the joint.[7] Platelet-rich plasma (PRP) is prepared using
autologous human plasma with an increased platelet concentration produced by centrifuging a
larger volume of a patient's blood. Preparations are further categorized into leukocyte-rich PRP
(LR-PRP) preparations, having leukocyte concentration above baseline, and leukocyte-poor PRP
(LP-PRP) preparations, having a leukocyte concentration below the baseline.[24] Similar to
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glucosamine sulfate, PRP injections are aimed at reducing KOA symptoms and act as a diseasemodifying or biological drug to help prevent the progression of KOA. Currently, according to the
American College of Rheumatology 2019 Osteoarthritis Guidelines, the use of PRP injections
for the treatment of knee and hip osteoarthritis is strongly recommended against.[3] Contrarily,
the American Academy of Orthopaedic Surgeons Clinical Practice Guidelines consortium
concluded that they "could not recommend for or against PRP in the treatment of symptomatic
knee osteoarthritis."[25] Inconsistent recommendations can cause provider and patient confusion
regarding alternative treatments or modalities. Can PRP injection be proven effective to reduce
pain related to symptomatic KOA or slow disease progression, therefore, limiting the use of
NSAIDs?
A systemic review by Shen et al. with 14 randomized control trials and comprising a total
of 1423 participants was performed to outline the efficacy of PRP injections compared to other
KOA treatments.[26] All studies were required to include at least one control group treated with
intra-articular hyaluronic acid, ozone, or corticosteroid injections. Primary efficacy outcomes
were measured using the WOMAC pain, physical function, and total scores at intervals of three,
six, and twelve months. Studies were not excluded based on the preparation of either LR-PRP or
LP-PRP.
WOMAC pain scores at three months were reported by several studies and were found to
be statistically significant and in favoring PRP injections versus control. Similar results were
demonstrated at both six- and twelve-month intervals. WOMAC physical function and total
scores at three, six, and twelve-month intervals were also found to be statistically significant and
in favor of PRP injections over intra-articular ozone, hyaluronic acid, and corticosteroid
injections. (Table 6.1-6.3, Appendix A) Only ten studies recorded adverse effects and there was
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found to be no statistically significant difference between PRP injections versus the other intraarticular injection's adverse effects. Non-specific adverse effects were recorded and included
pain, stiffness, syncope, dizziness, headache, nausea, gastritis, sweating, and tachycardia. All
adverse effects were monitored and resolved within a few days. Given the results of Shen et al.
intra-articular PRP injections are more effective than saline placebo, corticosteroid, ozone, and
hyaluronic acid injections at three, six, and twelve-month reporting.[26]
Another randomized control trial performed by Buendía-López et al. aimed at comparing
the efficacy of PRP injections versus intra-articular hyaluronic acid and oral NSAIDs in 106
participants.[27] The control group received 60mg etoricoxib to be taken concomitantly with
omeprazole for 52 weeks. The hyaluronic acid group received a single intra-articular injection of
DurolaneÓ, a high molecular weight hyaluronic acid preparation (60mg/2mL). Lastly, the PRP
group received a 5mL injection of LP-PRP prepared from 60 ml of peripheral blood extracted by
venipuncture of the antecubital vein. All participants were evaluated before initiation, at six
months, and twelve months. Efficacy outcomes were measured by a 20% decrease in WOMAC
pain, stiffness, and physical function scores. Secondary measures included the VAS score, x-ray,
and MRI progression. There was no statistically significant difference between the three groups
in either baseline measurements.
During the 6-month evaluation and regarding the primary outcome measures (WOMAC
pain, stiffness, and physical function), the rate of response to PRP was 30 percentage points
higher than the rate of response of NSAIDs (95% CI 26–32; P < 0.05). Secondary outcome
measures had similar results with the VAS being 30 percentage points higher than NSAIDs.
(95% CI 27-32). At the 12-month evaluation, the rate of responses between PRP and NSAIDs
remained nearly identical to results from the 6-month evaluation for both primary and secondary
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outcomes (Table 7.1-7.2, Appendix A). However, when comparing the PRP, HA, and NSAID
groups in reference to the cartilage thickness reduction or joint space narrowing, there was no
statistically significant difference. Therefore, it can be concluded PRP injections are effective in
reducing WOMAC pain, stiffness, physical function, and total scores better than hyaluronic acid
and oral NSAIDs at 12-month evaluations. On the other hand, the results from the study
demonstrate PRP injections may not have a positive effect on the progression of KOA and
cannot be used as a prophylactic measure to reduce joint space narrowing or cartilage
degeneration.[27]
Now that the efficacy of PRP injections over other treatments has been established is
there a difference in results based on the preparation? As previously mentioned, there are
currently two preparations available for PRP injections, leukocyte-poor (LP-PRP), and
leukocyte-rich (LR-PRP). During the study of the effect of PRP injections in rabbit tendons, high
concentrations of white blood cells (LR-PRP) were shown to increase the expression of catabolic
cascades and inflammatory markers such as interleukin-1 and tumor necrosis factor-alpha,
causing cell death.[29] On this evidence alone it would seem injections with less white blood cells
would be more suitable for medical or clinical interventions.
Riboh et al. aimed to demonstrate a difference between the PRP preparations by outlining
improvements of pain and comparing adverse effects. The authors compared data from six
randomized control studies and three prospective studies. First, they compared reductions in
WOMAC pain, stiffness, and physical function scores in PRP injections versus hyaluronic acid
and placebo injections. They further divided the results by comparing studies using either LRPRP or LP-PRP and which preparation provided the greatest reduction in WOMAC sub-scores.

Schmitz | Page 22
Finally, the authors compared adverse effects between both preparations of PRP injections and
hyaluronic acid injections.
Injection of LP-PRP resulted in significantly better WOMAC scores than did injection of
hyaluronic acid (mean difference, –21.14; 95% CI, –39.63 to –2.65) or placebo (mean difference,
–17.84; 95% CI, –34.95 to –0.73). No such difference was observed with LR-PRP (mean
difference, –14.28; 95% CI, –44.80 to 16.25).[29] The incidence of local adverse reactions was
greater in PRP injections than hyaluronic acid (odds ratio, 5.63; 95% CI, 1.38-22.90), but there
was surprisingly no difference in local adverse effects based on leukocyte concentration.[29]
Intra-articular Hyaluronic Acid Injections
Hyaluronic acid is a naturally occurring glycosaminoglycan found in the synovial fluid
and cartilage matrix. The pathogenesis of OA causes a decrease in both molecular weight and
concentration of hyaluronic acid in the synovial joint. It is thought that hyaluronic acid
temporarily restores the lubricating and shock-absorbing effects of synovial fluid and might also
have disease-modifying effects, such as reduction of synovial inflammation, protection against
cartilage erosion, and promotion of intra-articular hyaluronic acid production.[7] Clinically it is
derived from the combs of roosters or via in vitro bacterial fermentation. Benefits of treatment
with hyaluronic acid include a positive safety profile and a non-invasive procedure. However,
hyaluronic acid tends to be very expensive, health insurance coverage tends to be difficult to
acquire, and certain manufacturers or providers perform serial injections once weekly for three
weeks, which can be more expensive and time consuming for the patient. As noted earlier,
documented adverse effects for hyaluronate sodium therapy typically remain local such as
injection site irritation. Contrasting the adverse effects alone, hyaluronate sodium therapy may
seem more appealing to patients than NSAIDs, but is it equally or more effective?
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A randomized, double-blind, placebo-controlled trial performed by Petrella et al. was
conducted to determine the efficacy of hyaluronate sodium versus NSAIDs. The researchers used
subjective measures of pain, stiffness, disability at rest, and following walking or stepping
activities of 120 patients. These participants were divided into four randomized groups each
unaware of the treatment they were receiving. Group 1 received 2mL of hyaluronate sodium
intra-articular at a concentration of 10mg/mL and oral placebo (100mg lactose). Group 2
received diclofenac 75mg and misoprostol 200mg and hyaluronate sodium intra-articular. Group
3 was assigned diclofenac 75mg and placebo. Finally, group 4 was assigned oral lactose and
intra-articular saline as a placebo. The aforementioned measures were used to determine the
efficacy of treatments along with physical function testing. The physical function was
determined in two ways, first, the subjective WOMAC stiffness and physical disability subscores, second, a self-paced walking and self-paced stepping test were administered. The selfpaced walking test consisted of a 40-meter walk at a comfortable or "normal" pace chosen by the
participant. The self-paced stepping test consisted of stepping at a comfortable or "normal" pace
up and down 9.5-inch steps 20 times.
Self-reported and subjective pain using the WOMAC scores were similar at baseline in
all four groups. Groups one, two, and three showed a significant decrease in pain recorded on the
WOMAC global score at the four-week interval. Pain scores for groups one and three remained
the same as week four until termination of the study. However, group 2 demonstrated a
statistically significant improvement in pain (P =0.005). Similarly, groups one, two, and three,
showed statistically significant (P <0.05) improved in physical functioning at week four but
remained unchanged in group three until termination. Therefore groups one and three showed
further significant improvement (P <0.05) in week four until completion of the study. Finally, the
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results of the self-paced walking and stepping testing demonstrated similar results. Interestingly,
pain during rest and following the self-paced walking test was significantly (P <0.05) less in all
four groups following the four weeks follow up, while only groups one through three showed
improvement in the self-paced stepping at four weeks. Furthermore, there was no significant
difference or improvement in reported pain following the self-paced walking test in all four
groups after week four until termination. Interestingly, at week 12, group one had significantly
lower (P <0.05) improved pain following the self-paced stepping test, group two remained
unchanged, and groups three and four had significantly (P <0.05) higher pain scores.[38]
Another double-blind, randomized clinical trial aimed to determine the efficacy of
hyaluronic acid versus NSAIDs performed by Adams et al. reached a similar conclusion. They
divided 102 patients into three groups; group one received oral NSAIDS only, group two
received intra-articular hylan GF-20 only, and group three received both oral NSAIDs and intraarticular hylan GF-20. Participants were graded using the WOMAC and VAS scores and
followed for a total of 26 weeks. The results of the study support the use of hylan GF-20 or
hyaluronic acid for symptomatic treatment and management of patients diagnosed with KOA.
Furthermore, the results of Adams et al. support the hypothesis that treatment with hyaluronic
acid alone is at least as effective with NSAIDs alone.[39]
Intra-articular Dextrose Prolotherapy
Prolotherapy involves the injection of a hypertonic irritant solution, usually a
combination of normal saline and dextrose, into damaged tissue such as cartilage to encourage
cell proliferation. The exact mechanism of action is unknown; however, the current belief is the
solution creates a hyperosmolar environment and the irritant induces inflammatory cascades and
stimulates the local healing of cells and release of platelet-derived growth factor.[37] As
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previously mentioned, the solution typically contains dextrose, normal saline, and a local
anesthetic administered before or during the procedure. Prolotherapy can be very appealing due
to the large availability of these medications or solutes. On the other hand, when discussing
prolotherapy with possible patients who may benefit, understanding the need for routine or serial
injections must be achieved. The usual regimen includes more than one injection monthly, most
often patients receive upwards of three or four per month. With the need for serial injections, is
prolotherapy feasible for patients when oral medications or other treatments require less
commitment? A quality improvement project performed by Rabago et al. aimed to answer this
question by inviting patients suffering from symptomatic KOA whose insurance plan covered
prolotherapy injection to a primary care office to receive these injections. Feasibility was
measured by the acceptance rate of the invitation and acceptability was measured by patient
adherence and satisfaction with three or more prolotherapy injections. In total, thirty-nine
patients were invited to receive the injections, eleven responded and only seven received three or
more injections. The authors believed an acceptance rate of 18% was satisfactory and concluded
prolotherapy is a feasible option to be performed in an outpatient or primary care clinical setting.
[36]

Prolotherapy has been proven to be feasible and cost-efficient, however, is it effective in the

symptomatic management of KOA?
The efficacy of PRP has been discussed previously and a randomized, double-blind,
clinical study aimed at comparing prolotherapy with PRP. 42 patients were enrolled in the study,
one group was to receive a 7mL PRP injection as a control (n=21) and the study group (n=21)
was to receive a 7mL 25% dextrose injection. The participants were admitted into the operating
room and knee symptoms were measured using the WOMAC scores at baseline. Each patient
received the same routine monitoring processes including blood pressure, heart rate, ECG, and a
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20mL blood sample. The 20mL blood sample was then placed in a centrifuge and the separated
plasma was prepared for the 7mL PRP injection in the control group. Using ultrasound guidance
and the anterolateral approach either the 7mL PRP or 7mL dextrose was injected intra-articular,
neither the provider nor the participant were aware of the contents. The same procedure was then
repeated one month later for all patients.
Before initiation of treatment, there was no statistical significance in the baseline
WOMAC scores or demographics between the control and study group. The results of the study
show a statistically significant decrease in pain, stiffness, and physical limitation subscores in all
follow-up intervals for both PRP and prolotherapy injections. A similar pattern of relief was
noticed in both treatments in which, subscores were gradually and progressively decreasing for
the first two months and by the six months began to slowly increase once again. (Table 8.1-8.3,
Appendix A).[33] Comparably the WOMAC total scores for both groups followed the same
pattern of improvement (Table 8.4, Appendix A).[33] While the statistical improvement in all
efficacy outcomes during the follow-up intervals for both injections was demonstrated, according
to the results PRP injection provides more improvement and longer when compared to
prolotherapy.[33]
Intra-articular Mesenchymal Stem Cell Injections
Therapy to help improve the patient's symptoms and hinder the progression of a specific
disease has been the goal of research for years, not only related to osteoarthritis but all
pathologies. One promising therapy is the use of stem cells in both symptomatic resolution and
regenerative medicine. Stem cells are a difficult discussion due to ethical challenges in obtaining
cells and the advanced scientific knowledge required to understand the origin and complex
differentiation potential. Speaking generally there are typically five classes or potentials for stem
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cells, omnipotent, pluripotent, multipotent, oligopotent, and unipotent. Omnipotent, occasionally
called totipotent, has the most differentiation potential, these cells can develop in embryonic and
extra-embryonic tissues. The most important characteristic of omnipotent is the ability to
differentiate and generate a fully functional living organism and are most recognizable as a
zygote. Pluripotent stem cells are typically derived from embryonic stem cells or induced
pluripotent stem cells (iPS cells). These cells can self-renew and differentiate into three germ
layers comprising human tissues and organs; ectoderm, endoderm, and mesoderm. Multipotent
stem cells, similar to pluripotent, also can self-renew and differentiate into specific cell types.
The most common example and the focus in osteoarthritis treatment are mesenchymal stem cells
(MSC), which can differentiate into osteoblasts, myocytes, adipocytes, and chondrocytes. One
benefit of MSC is the ability to harvest these types of cells ethically, safely, and without
advanced procedures. Oligopotent stem cells also can self-renew and differentiate but are very
limited in ability and typically only differentiate into closely related types. Hematopoietic stem
cells (HSC) are the most common example of oligopotent stem cells; these cells are derived from
mesoderm and differentiate into other blood cell types. Finally, unipotent stem cells are the least
potent and most limited stem cell type. While they can self-renew and differentiate, they are
unidirectional in their differentiation capacity and only differentiate into a single cell type.[30]
Multipotent stem cells, particularly multipotent stem cells, have been the interest of
researchers for several years aiming to discover osteoarthritis treatments with potential
restorative or regenerative mechanisms. In recent years, MSCs have been the most promising
due to their highly available origin in the body and the potent ability to self-renew and
differentiate. The most important and useful characteristic for MSCs is the non-immunogenic
profiles. In other words, allogenic transplantation can be performed without the need for
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immunosuppression. The three most common origins of MSCs used in research are derived from
adipose tissue, bone marrow, and umbilical cord.[31] Adipose-derived stem cells are derived from
the stromal vascular fraction (SVF) in the subcutaneous tissues. They are plastic adherent and
possess adipogenic, osteogenic, chondrogenic, myogenic, cardiogenic, and neurogenic potential
in vitro.[31] As the name suggests, bone marrow-derived stems cells originate in the bone marrow
and are thus harvested from this source. Bone marrow harvesting is considered the most invasive
and painful procedure to harvest MSCs and requires general anesthesia plus several days for
hospital care. Finally, umbilical cord-derived stem cells can be isolated from several different
parts of the cord including, Wharton's Jelly, cord lining, and peri-vascular region. However,
almost studies used MSCs that were derived from cord blood and Wharton's jelly.[31] Benefits
and risks will not be discussed at length for each of these stem cells, regardless, the basic
harvesting techniques and location must be understood before proceeding to discuss medical
benefits in regenerative osteoarthritis treatment.
In a randomized control study performed by Vega et al. mesenchymal stem cells were
compared to hyaluronic acid in participants with symptomatic KOA. 30 participants who
previously failed other conservative managements were selected and placed into two groups, one
group received intra-articular hyaluronic acid injections and the other group received allogenic
bone marrow mesenchymal stem cell therapy by intra-articular injection of 40x106 cells.
Outcomes were followed for one year using the VAS score, WOMAC score, and Lequesne
functional index. Also, MRI studies using T2 mapping were performed at baseline, six months,
and one year to evaluate for articular cartilage quality using the poor cartilage index (PCI).
Comparing the control versus experimental groups VAS scores and WOMAC sub-scores
at the six months and one year follow up, both groups experienced a consistent reduction in
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scores. However, the MSC group experienced a statistically significant change in both VAS and
WOMAC sub-scores at the aforementioned follow-ups (Figure 4.2, Appendix B).[32] The
WOMAC general and Lequesne scores changed consistently for both groups, with significant
decreases at six months and one year in the experimental group and no statistically significant
change in the control group (Figure 4.1, Appendix B).[32] Similarly, the T2 mapping on MRI
showed a decrease in the PCI for both groups, but the decrease was not statistically significant in
the control group, while at the one year follow up it reached significance (P<0.05) in the MSC
group.[32] The results validate the safety of allogeneic MSCs while simultaneously providing
indications for their efficacy in treating osteoarthritis compared to other conventional KOA
treatments. Furthermore, allogenic MSC treatment is shown to aid in cartilage repair and
regeneration, possibly decreasing symptoms and progression related to KOA.
Conclusion
NSAID therapy has been the mainstay of osteoarthritis treatment because the goal of
therapy is reducing pain and therefore improving physical functioning and quality of life.
However, treatment with oral and topical NSAIDs are effective with pain management but no
consistent long-term improvement of physical function with the use of NSAIDs alone has been
reported.[38] Along with no improvement of physical function, there is a multitude of adverse
effects of NSAIDs such as gastrointestinal complaints, ulcerations, cardiovascular complications,
and renal clearance restrictions which can all limit their use in the older population. If modest
pain reduction is the only goal NSAIDs can achieve, then alternative treatments are not only
recommended but should be required for patients to improve their physical functioning and
quality of life.
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The effectiveness of land-based or aquatic exercise has been studied and proven in
numerous studies. The magnitude of the pain relief, about 25%[42], would be considered small,
but comparable to estimates reported for non-steroidal anti-inflammatory drugs.[41] Nonetheless,
exercise will statistically and subjectively improve physical function and quality of life.[40-43]
Another advantage physical activity has over NSAIDs, is the ability to possibly limit disease
progression or prevent osteoarthritis. During gait, body weight is transferred onto the knee with
substantial leverage, so that each additional kilogram of body mass increases the compressive
load over the knee by roughly four kg.[40] For example, if a patient safely lost ten pounds, the
compressive load on their knees would be reduced by roughly 40 pounds. Moderate weight loss,
5% of total body weight or intensive weight loss, 10% of total body weight, in older overweight
and obese adults with KOA has positive effects on clinical and mechanistic outcomes, with a
clear dose‐response effect.[5] Land-based and aquatic physical therapy should be performed at
least three times per week for prevention and treatment of osteoarthritis, in turn, this will
decrease disease progression and limit the need for NSAID treatment.[40-43]
Oral and intra-articular corticosteroids are more potent inhibitors of inflammatory
mediators and their efficacy for osteoarthritis has been clinically proven. In a 2019 foundation
guideline, the American College of Rheumatology strongly recommends the use of intra-articular
corticosteroids for the treatment of both hip and knee osteoarthritis.[3] According to Gotzsche et
al., oral prednisone bursts are more effective at reducing pain with activity and joint line
tenderness.[9] However, extended daily therapy for symptomatic treatment is not feasible due to
the safety profile and adverse effects. Therefore, oral corticosteroid therapy can be helpful in
patients suffering from advanced osteoarthritis with severe pain and tenderness or symptomatic
osteoarthritis affecting several joints. Intra-articular corticosteroid injections appear to have a
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better safety profile with less systemic adverse effects but a less than an ideal reduction in pain.
According to the studies of Dieu-Donné et al., intra-articular corticosteroids have a better
reduction in pain and physical improvement compared to NSAIDs but their efficacy is brief.[12]
Thus, the clinic use of intra-articular corticosteroids may be reserved best for patients whose pain
is not well controlled with daily physical activity and oral/topical NSAIDs. Additionally, the
regimen appearing to provide the most relief is an intra-articular corticosteroid injection followed
by as needed per day oral NSAIDs.[12]
For patients not willing to receive an intra-articular injection but still longing to pain
relief due to their KOA, duloxetine has proven its efficacy as an alternative or additional
treatment.[17-18] As previously discussed, central sensitization may prove to be an equal
contributor to pain generation in KOA, and treatment with duloxetine alters this pathway. While
selective serotonin and norepinephrine reuptake inhibitors have numerous adverse effects, they
are typically well handled and can help reduce symptoms related to KOA. Regardless of prior
treatments, the use of duloxetine will reduce pain and limit the need for rescue medications such
as NSAIDs or tramadol.[17] Flares of pain related to KOA and synovitis can be reduced using
NSAIDs while adjuvant use of daily duloxetine will help reduce the secondary pain pathway,
resulting in an optimal reduction in pain. Similarly, Myers et al. outlined the efficacy of
duloxetine compared to other oral daily and rescue medications. Duloxetine is clinically more
effective than tramadol, celecoxib, hydromorphone, and oxycodone and should be conditionally
recommended for symptomatic KOA.[3,18]
Due to allergic sensitivities, contraindications, or other comorbidities, NSAIDs may be
restricted or limited in certain patient populations suffering from symptomatic KOA. Ozone
therapy is a safe and low-cost procedure proven to be effective in reducing pain related to KOA
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and post-arthroscopic procedures.[19-23] Wang et al. demonstrated the efficacy of intra-articular
ozone versus placebo following an arthroscopic debridement secondary to symptomatic KOA.
After 12 weeks patients who received intra-articular ozone had reduced pain and disability and
increased functional ability. Ozone therapy should not be the only medication used for
orthopedic related post-operative pain management; however, it can be used concomitantly with
other measures if needed. Additionally, ozone therapy can result in faster pain relief and
functional improvement than NSAIDs for a short period.[22] The use of intra-articular ozone can
be used to help decrease post-procedural pain or severe flares of KOA related pain, but long-term
efficacy is non-superior to NSAIDs.[19-23]
KOA is a chronic and progressive disease; therefore much effort is being placed in
regenerative and restorative medicine. Glucosamine sulfate appears to be the most cost-effective
disease-modifying drug available today. Unfortunately, glucosamine sulfate does very little in
the management of pain related to osteoarthritis and should not be used in this manner. Selvan et
al. demonstrated the use of glucosamine sulfate and NSAIDs is more effective at reducing
WOMAC total scores than NSAID use alone.[15] Daily use of glucosamine sulfate has been
proven to slow the progression of mild to moderate KOA and therefore possibly limit the need
for further interventions and medications.[15-16] Despite the extensive studies demonstrating the
efficacy of glucosamine in KOA, the American College of Rheumatology strongly recommends
against the use.[3]
The use of LR-PRP and LP-PRP has numerous studies and analyses demonstrating its
efficacy in pain reduction. Improving the quality of life, and possibly altering disease
progression of KOA. Surprisingly, according to the American College of Rheumatology 2019
Osteoarthritis Guidelines, the use of PRP injections for the treatment of knee and hip
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osteoarthritis is strongly recommended against.[3] On the other hand, intra-articular
corticosteroids are strongly recommended for KOA. However, according to the meta-analysis of
Shen et al., PRP therapy reduced WOMAC total scores better than intra-articular ozone,
hyaluronic acid, and corticosteroids, at three, six, and twelve months.[26] Likewise, the adverse
reactions are mostly limited to local injection reactions rather than the multitude of
corticosteroids. If an injection performs better compared to standard therapy and with less
adverse reactions, this therapy should be recommended or attempted in patients with continued
symptomatic KOA.[24-29]
One of the most common complaints from patients suffering symptomatic KOA is the
pain or joint line tenderness during and following activity. NSAIDs can decrease pain before
activity if taken appropriately concerning time and duration. They also are effective and
decreasing post-activity pain, but dosing restrictions typically limit usage before and after
activity consumption. Therefore, hyaluronic acid may be more beneficial in patients seeking to
remain physically active after a diagnosis of KOA has been made. It seems hyaluronate sodium
therapy may show greater efficacy for activity-related pain and improvement of performance
than NSAIDs or exercise therapy alone.[39] Not only may they be more effective but there is no
daily or multiple times daily consumption requirements, making hyaluronic acid effective,
efficient, and convenient. Hyaluronic acid increased functional ability in patients performing
walking and stepping exercises, allowing them to walk farther and faster when compared to
NSAIDs.[38] Given the data, treatment in patients with early symptomatic KOA may benefit from
intra-articular hyaluronic acid treatments to maintain pain control and functional ability.[38-39]
Hypertonic solutions typically containing dextrose have been used in orthopedics for
chronic tendinosis, muscle pain, or joint pain over the last several years. The mechanism of
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action is not well established but it has shown promise in reducing pain related to osteoarthritis.
According to Hung et al., prolotherapy is almost as equally effective as PRP, it is cheaper and
can be covered by health insurance plans.[37] Prolotherapy does require serial injections to be
performed weekly but patients are more likely and willing to participate if there is evidence of
success and the treatment is cheaper than other alternatives.[36] The use of prolotherapy has been
deemed not recommended by the American College of Rheumatology, however, the
effectiveness has been demonstrated, and the treatment boasts an excellent safety profile.[3,37]
Mesenchymal stem cell therapy with the use of adipose stem cells is the new and
emerging therapy for symptomatic KOA. While this therapy is strongly recommended against by
the American College of Rheumatology, there is much evidence to support its use.[3,31,32,34,35]
Compared to the control group, the MSC group experienced a statistically significant change in
both VAS and WOMAC sub-scores and improved Lequesne at the one year follow up.[32]
Allogenic MSC therapy has been shown to aid in cartilage repair by evidence of T2 mapping at
serial follow-ups.[32] According to the studies of Vega et al. MSC therapy was proven more
effective than intra-articular hyaluronic acid injections at recommended follow-ups.[32] Finally,
there is clinical data to support the use of MSCs in patients suffering from hip, ankle, and knee
osteoarthritis for both symptomatic management and possible disease modification.[35]
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Appendix A
Tables
Table 1
Lifetime risk probabilities and 95% CIs for
symptomatic knee OA, stratified and overall*

Table 2
Comparison of Oral Corticosteroids vs NSAIDs
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Table 3
Efficacy of NSAIDs vs intra-articular steroids on pain and Lequesne index from initiation until
day 42

Table 4.
Indirect comparison of WOMAC total score change from baseline. [18]

Table 5
VAS, Lequesne and WOMAC scores in the Ozone and Control groups at Baseline, at 6 weeks
and at 3, 6 and 12 months after treatment.[21]
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Table 6.1 Comparison of WOMAC pain scores at 3, 6, and 12-month intervals.[26]
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Table 6.2 Comparison of WOMAC physical function scores at 3, 6, and 12-month intervals.[26]

Table 6.3. Comparison of total WOMAC score at 3, 6, and 12-month intervals.[26]
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Table 7.1
Comparison of outcomes at 6 months.[27]

Table 7.2
Comparison of outcomes at 12 months.[27]
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Table 8.1
Comparison of functional limitation between the PRP and PRL groups. [33]

Table 8.2
Comparison of pain between the PRP and PRL groups [33]

Table 8.3
Comparison of stiffness between the PRP and PRL groups [33]

Table 8.4
Comparison of WOMAC scores between the PRP and PRL groups [33]

Table 9
Outcomes measure for Kovar et al. at baseline and after intervention.[42]
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Appendix B
Figures
Figure 1
Joint space narrowing in patients completing each year of the study. [16]

Figure 2
Visit-wise change from baseline mean BPI average pain severity score in all subgroups.[17]
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Figure 3.1

Lequesne scores in the groups pre- and post-treatment.
P<0.05 vs control group; P<0.05 vs. baseline

Figure 3.2

VAS scores in the groups pre- and post-treatment. P<0.05
vs. control group; P<0.05 vs. baseline. VAS, Visual
Analogue Scale

Figure 4.1

Comparison of Lesquesne and WOMAC general scores in the hyaluronic acid group versus MSC.[32]

Figure 4.2

Comparison of VAS and WOMAC pain sub-scores in hyaluronic acid versus MSC.[32]
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Figure 5
Risk factors for development or progression of knee osteoarthritis.[40]

